The Psen1-L166P-knock-in mutation leads to amyloid deposition in human wild-type amyloid precursor protein YAC transgenic mice

Ruben Vidal, Neeraja Sammeta, Holly Garringer, Kumar Sambamurti, Leticia Miravalle, Bruce Lamb, Bernardino Ghetti

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Genetically engineered mice have been generated to model cerebral β-amyloidosis, one of the hallmarks of Alzheimer disease (AD) pathology, based on the overexpression of a mutated cDNA of the amyloid-β precursor protein (AβPP) or by knock-in of the murine Aβpp gene alone or with presenilin1 mutations. Here we describe the generation and initial characterization of a new mouse line based on the presence of 2 copies of the human genomic region encoding the wild-type AβPP and the L166P presenilin 1 mutation. At ~6 mo of age, double-mutant mice develop amyloid pathology, with signs of neuritic dystrophy, intracellular Aβ accumulation, and glial inflammation, an increase in AβPP C-terminal fragments, and an 8 times increase in Aβ42 levels with a 40% decrease in Aβ40 levels, leading to a significant increase (14 times) of Aβ42/Aβ40 ratios, with minimal effects on presenilin or the Notch1 pathway in the brain. We conclude that in mice, neither mutations in AβPP nor overexpression of an AβPP isoform are a prerequisite for Aβ pathology. This model will allow the study of AD pathogenesis and testing of therapeutic strategies in a more relevant environment without experimental artifacts due to the overexpression of a single-mutant AβPP isoform using exogenous promoters.

Original languageEnglish
Pages (from-to)2899-2910
Number of pages12
JournalFASEB Journal
Volume26
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Amyloid beta-Protein Precursor
Pathology
Amyloid
Transgenic Mice
Mutation
Protein Isoforms
Presenilins
Presenilin-1
Alzheimer Disease
Protein C
Application programs
Brain
Mutant Proteins
Complementary DNA
Genes
Neuroglia
Artifacts
Testing
Inflammation
Therapeutics

Keywords

  • AβPP processing
  • Animal model
  • Presenilin

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Genetics
  • Molecular Biology

Cite this

The Psen1-L166P-knock-in mutation leads to amyloid deposition in human wild-type amyloid precursor protein YAC transgenic mice. / Vidal, Ruben; Sammeta, Neeraja; Garringer, Holly; Sambamurti, Kumar; Miravalle, Leticia; Lamb, Bruce; Ghetti, Bernardino.

In: FASEB Journal, Vol. 26, No. 7, 07.2012, p. 2899-2910.

Research output: Contribution to journalArticle

@article{ec3e27025f4d4a52b767bb45699ee739,
title = "The Psen1-L166P-knock-in mutation leads to amyloid deposition in human wild-type amyloid precursor protein YAC transgenic mice",
abstract = "Genetically engineered mice have been generated to model cerebral β-amyloidosis, one of the hallmarks of Alzheimer disease (AD) pathology, based on the overexpression of a mutated cDNA of the amyloid-β precursor protein (AβPP) or by knock-in of the murine Aβpp gene alone or with presenilin1 mutations. Here we describe the generation and initial characterization of a new mouse line based on the presence of 2 copies of the human genomic region encoding the wild-type AβPP and the L166P presenilin 1 mutation. At ~6 mo of age, double-mutant mice develop amyloid pathology, with signs of neuritic dystrophy, intracellular Aβ accumulation, and glial inflammation, an increase in AβPP C-terminal fragments, and an 8 times increase in Aβ42 levels with a 40{\%} decrease in Aβ40 levels, leading to a significant increase (14 times) of Aβ42/Aβ40 ratios, with minimal effects on presenilin or the Notch1 pathway in the brain. We conclude that in mice, neither mutations in AβPP nor overexpression of an AβPP isoform are a prerequisite for Aβ pathology. This model will allow the study of AD pathogenesis and testing of therapeutic strategies in a more relevant environment without experimental artifacts due to the overexpression of a single-mutant AβPP isoform using exogenous promoters.",
keywords = "AβPP processing, Animal model, Presenilin",
author = "Ruben Vidal and Neeraja Sammeta and Holly Garringer and Kumar Sambamurti and Leticia Miravalle and Bruce Lamb and Bernardino Ghetti",
year = "2012",
month = "7",
doi = "10.1096/fj.12-205542",
language = "English",
volume = "26",
pages = "2899--2910",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "7",

}

TY - JOUR

T1 - The Psen1-L166P-knock-in mutation leads to amyloid deposition in human wild-type amyloid precursor protein YAC transgenic mice

AU - Vidal, Ruben

AU - Sammeta, Neeraja

AU - Garringer, Holly

AU - Sambamurti, Kumar

AU - Miravalle, Leticia

AU - Lamb, Bruce

AU - Ghetti, Bernardino

PY - 2012/7

Y1 - 2012/7

N2 - Genetically engineered mice have been generated to model cerebral β-amyloidosis, one of the hallmarks of Alzheimer disease (AD) pathology, based on the overexpression of a mutated cDNA of the amyloid-β precursor protein (AβPP) or by knock-in of the murine Aβpp gene alone or with presenilin1 mutations. Here we describe the generation and initial characterization of a new mouse line based on the presence of 2 copies of the human genomic region encoding the wild-type AβPP and the L166P presenilin 1 mutation. At ~6 mo of age, double-mutant mice develop amyloid pathology, with signs of neuritic dystrophy, intracellular Aβ accumulation, and glial inflammation, an increase in AβPP C-terminal fragments, and an 8 times increase in Aβ42 levels with a 40% decrease in Aβ40 levels, leading to a significant increase (14 times) of Aβ42/Aβ40 ratios, with minimal effects on presenilin or the Notch1 pathway in the brain. We conclude that in mice, neither mutations in AβPP nor overexpression of an AβPP isoform are a prerequisite for Aβ pathology. This model will allow the study of AD pathogenesis and testing of therapeutic strategies in a more relevant environment without experimental artifacts due to the overexpression of a single-mutant AβPP isoform using exogenous promoters.

AB - Genetically engineered mice have been generated to model cerebral β-amyloidosis, one of the hallmarks of Alzheimer disease (AD) pathology, based on the overexpression of a mutated cDNA of the amyloid-β precursor protein (AβPP) or by knock-in of the murine Aβpp gene alone or with presenilin1 mutations. Here we describe the generation and initial characterization of a new mouse line based on the presence of 2 copies of the human genomic region encoding the wild-type AβPP and the L166P presenilin 1 mutation. At ~6 mo of age, double-mutant mice develop amyloid pathology, with signs of neuritic dystrophy, intracellular Aβ accumulation, and glial inflammation, an increase in AβPP C-terminal fragments, and an 8 times increase in Aβ42 levels with a 40% decrease in Aβ40 levels, leading to a significant increase (14 times) of Aβ42/Aβ40 ratios, with minimal effects on presenilin or the Notch1 pathway in the brain. We conclude that in mice, neither mutations in AβPP nor overexpression of an AβPP isoform are a prerequisite for Aβ pathology. This model will allow the study of AD pathogenesis and testing of therapeutic strategies in a more relevant environment without experimental artifacts due to the overexpression of a single-mutant AβPP isoform using exogenous promoters.

KW - AβPP processing

KW - Animal model

KW - Presenilin

UR - http://www.scopus.com/inward/record.url?scp=84863201651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863201651&partnerID=8YFLogxK

U2 - 10.1096/fj.12-205542

DO - 10.1096/fj.12-205542

M3 - Article

VL - 26

SP - 2899

EP - 2910

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 7

ER -